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Insulin and adrenergic stimulation are two divergent
regulatory systems that may interact under certain
pathophysiological circumstances. Here, we character-
ized a complex consisting of insulin receptor (IR) and b2-
adrenergic receptor (b2AR) in the heart. The IR/b2AR
complex undergoes dynamic dissociation under diverse
conditions such as Langendorff perfusions of hearts with
insulin or after euglycemic-hyperinsulinemic clamps in
vivo. Activation of IR with insulin induces protein kinase
A (PKA) and G-protein receptor kinase 2 (GRK2) phos-
phorylation of the b2AR, which promotes b2AR coupling
to the inhibitory G-protein, Gi. The insulin-induced phos-
phorylation of b2AR is dependent on IRS1 and IRS2.
After insulin pretreatment, the activated b2AR-Gi sig-
naling effectively attenuates cAMP/PKA activity after
b-adrenergic stimulation in cardiomyocytes and conse-
quently inhibits PKA phosphorylation of phospholamban
and contractile responses in myocytes in vitro and in
Langendorff perfused hearts. These data indicate that
increased IR signaling, as occurs in hyperinsulinemic
states, may directly impair bAR-regulated cardiac con-
tractility. This b2AR-dependent IR and bAR signaling
cross-talk offers a molecular basis for the broad inter-
action between these signaling cascades in the heart
and other tissues or organs that may contribute to the
pathophysiology of metabolic and cardiovascular dys-
function in insulin-resistant states.
Insulin and adrenergic stimulation represent two diver-
gent regulatory systems that interact with overlapping
signaling pathways in adipocytes, liver, and skeletal and
cardiac muscle. Hyperinsulinemia is a uniform character-
istic of obesity and type 2 diabetes (1), which increases
insulin receptor (IR) signaling in the myocardium (2). It
was recently demonstrated that hyperactivation of insulin
signaling in the myocardium contributes to adverse left
ventricular (LV) remodeling in pressure overload cardiac
hypertrophy (induced by transverse aortic constriction)
(3). Heart failure, which is associated with elevated
sympathetic adrenergic activity, is characterized by gen-
eralized insulin resistance, hyperinsulinemia (4), and
impaired insulin-mediated glucose uptake in the myocar-
dium (2). Diabetes and obesity increase the risk of heart
failure and induce cardiac dysfunction, which has been
termed diabetic cardiomyopathy (5,6). Given that dys-
function of these regulatory systems commonly occurs
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in cardiovascular diseases (7–9), it is likely that molecular
cross-talk between insulin and adrenergic receptor regu-
latory systems exists within the cardiovascular system.
Stimulation of b-adrenergic receptors (bARs), which
are prototypical members of the G-protein–coupled recep-
tor superfamily, is best known for its regulation of con-
tractile function in the heart. Ligand binding to bARs
induces cAMP-dependent protein kinase A (PKA) activa-
tion (10) leading to phosphorylation of various substrates
including phospholamban (PLB) (10–12) to increase myo-
cyte contractility, stroke volume, and cardiac output (13).
Among the cardiac bARs, b1AR is the major subtype that
couples to the stimulatory G protein, Gs, to stimulate
contractile function, whereas b2AR is able to couple to
both Gs and Gi but with minimal effect on contractile
function (10–12). Conversely, activation of IRs, which
are receptor tyrosine kinases, promotes phosphorylation
of IR substrates (IRS-1 and -2) leading to Akt activation,
which promotes glucose uptake, glucose metabolism, and
insulin-mediated cardiac and skeletal muscle growth (14).
Stimulation of bARs also increases glucose uptake in car-
diac and skeletal muscle cells (15,16). Insulin and adren-
ergic stimulation share common downstream signaling
components including Gi (17), arrestin (18), and G-protein
receptor kinase (GRK)2 (16,19,20). Stimulation with either
insulin or adrenergic receptors antagonizes the ability of
the other to activate glucose transport (8) and to modu-
late myocyte survival (21).
An earlier study suggested that insulin augmented
adrenergic stimulation of contractility in isolated papil-
lary muscles (22). However, in an ischemia-reperfusion
study, insulin inhibited b-adrenergic responses in the
heart(s) (23). Also, phosphatidylinositol 3-kinase, a down-
stream kinase in the insulin signaling pathway, inhibits
b-adrenergic–induced contractile responses in isolated
cardiomyocytes (24). Earlier studies revealed that insulin
induced b2AR phosphorylation and internalization in
HEK293 cells and adipocytes (25–27); however, a compre-
hensive understanding of the molecular mechanisms un-
derlying insulin’s effects on b2AR signaling in the heart
remains to be achieved.
In this study, we characterized signaling cross-talk in
which IRs and b2ARs form a novel complex in the heart.
This complex directly exerts a b2AR-dependent impact on
intracellular transduction of bAR signaling pathways that
regulate cardiac contractility in cardiomyocytes and the
myocardium. Stimulation of IR promotes IRS-dependent
and GRK2-mediated phosphorylation of b2AR in isolated
cardiomyocytes and in ex vivo Langendorff perfused
hearts or after euglycemic-hyperinsulinemic clamps in
vivo. Stimulation of the IR also promotes dissociation of
the b2AR-IR complex and promotes b2AR internalization.
Internalization of b2AR selectively promotes Gi coupling
to attenuate cAMP/PKA signaling (28), which inhibits
contractile response in isolated neonatal and adult car-
diomyocytes and in Langendorff perfused hearts. Our
results not only underscore the critical role of signaling
cross-talk and integration between IR and bARs for con-
tractile regulation in the myocardium but also provide
a potential general mechanism to understand cross-talk
between IR and bAR regulatory systems in other meta-
bolic disorders and cardiac diseases.
RESEARCH DESIGN AND METHODS
Langendorff Perfusion Heart Preparation
Animal experiments were performed following the Na-
tional Institutes of Health Guide for the Care and Use of
Laboratory Animals. All procedures were approved by the
Institutional Animal Care and Use Committees at the
University of California, Davis; the University of Utah;
Temple University; and the Carver College of Medicine of
the University of Iowa. The isolated heart perfusion
technique was described previously (29). Hearts were ex-
cised from mice under anesthesia (120 mg/kg body wt i.p.
sodium pentobarbital) and were rapidly placed on a
Langendorff apparatus. Hearts were perfused at a constant
pressure of 80 mmHg with a solution containing 113.8
mmol/L NaCl, 22 mmol/L NaHCO3, 4.7 mmol/L KCl, 1.2
mmol/L KH2PO4, 1.1 mmol/L MgSO4, 11 mmol/L glu-
cose, 2 mmol/L CaCl2, and 2 mmol/L Na-pyruvate and
aerated with 95% oxygen and 5% carbon dioxide, pH
7.35–7.4, to which was added isoproterenol (ISO) at
concentrations ranging from 10-14 to 10-6 (mol/L). A
water-filled balloon was inserted into the left ventricle
and adjusted to achieve a LV end diastolic pressure of 10
mmHg. The balloon was connected to a Millar pressure
system (Millar Instruments, Houston, TX), and the pres-
sure was measured with a pressure catheter (SPR-671;
Millar Instruments) connected to an ADInstruments
PowerLab 16/30 with LabChart Pro-6.0 (ADInstruments,
Boston, MA). The heart rate was maintained at 480 bpm
by pacing the right ventricle with a Grass SD9 Stimula-
tor. Once a stable effect of the previous dose (;5 min)
was obtained, the next dose was applied. LV pressure, LV
end diastolic pressure, and the maximum rate of positive
and negative change (dP/dt) in LV pressure were recorded.
Data were analyzed offline with LabChart Pro-6.0.
Euglycemic-Hyperinsulinemic Clamps
Euglycemic-hyperinsulinemic clamps were performed in
nonsedated mice as previously described with minor changes
(30). In summary, the mouse jugular vein was catheter-
ized under tribromoethanol anesthesia (250 mg/kg body
wt by single intraperitoneal injection). Mice were allowed
to recover for 5 days with one heparin flush on day 3 be-
fore the clamp procedure. All mice were fasted overnight
before the clamp procedure day to synchronize the met-
abolic state. On the day of the procedure, mice were sin-
gle housed in a standard housing cage with a tether arm
attached to the catheter. A dual infusion pump (Harvard
Apparatus, Boston, MA) was used to infuse insulin at
a constant flow rate (10 mU/kg/min). A glucose solution
was infused at a variable rate to maintain plasma glucose
at a target value of 75–110 mg/dL and held at that level
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for 60 min. A comparable rate of saline infusion was used
as control. Glucose was monitored using tail vein blood
at 5-min intervals with a glucometer (Glucometer Elite;
Bayer, Tarrytown, NY).
Isolated Working Heart Perfusions and Intraperitoneal
Injection
Mouse hearts were isolated from anesthetized mice and
perfused in the working mode in Krebs-Henseleit buffer
supplemented with 5 mmol/L glucose and 0.4 mmol/L
palmitate in the presence or absence of 1 nmol/L in-
sulin as previously described by our group (31). Cardiac-
restricted IRS1-KO and IRS2-KO mice were injected with
isoproterenol (ISO) (2 mg/kg) for 10 min. The hearts
were harvested for Western blot.
Cell Culture
Neonatal cardiomyocytes were isolated from 1- to 2-
day-old wild-type, b1AR-KO, and b2AR-KO and cardiac-
restricted IRS1-KO and IRS2-KO mouse pups. Adult
mouse cardiomyocytes were isolated from wild-type and
mutant (mut) mice as indicated and cultured as described
previously (32). Adult rat cardiomyocytes were provided by
Dr. Donald Bers (University of California, Davis). In a sub-
set of experiments, H9c2 cardiomyoblasts were cultured in
DMEM plus 10% FBS for experiments.
Adenovirus Infection and Plasmid Transfection
Neonatal and adult cardiomyocytes were infected with
adenoviruses (100 multiplicity of infection) as previously
described to express the PKA activity biosensor (A-kinase
activity reporter 3 [AKAR3] [33]) or the cAMP biosensor
(indicator of cAMP using epac 3 [ICUE3] [32]) or C terminal
of inhibitory G protein [Gi-ct], GFP-bARKct, Flag-b2AR,
Flag-GRKmut b2AR, or Flag-PKAmut b2AR (28) as indicated
for 24 h. Small interfering RNA oligos targeting the mouse
IR (IDT, Coralville, IA) were transfected into wild-type neo-
natal cardiomyocytes, and experiments were conducted af-
ter 48 h expression. GRK2, IRS1, and IRS2 mouse small
hairpin RNA (shRNA) plasmids (Sigma-Aldrich, St. Louis,
MO) were used to create recombinant lentiviruses. Neo-
natal cardiomyocytes were infected with GRK2 shRNA,
IRS1 shRNA, or IRS2 shRNA lentivirus for 24 h and
cultured for an additional 48 h.
Fluorescent Resonance Energy Transfer Measurement
Myocytes expressing PKA or cAMP biosensors were
rinsed and maintained in PBS for fluorescent resonance
energy transfer (FRET) recordings (32). Cells were im-
aged on a Zeiss Axiovert 200M microscope with a
403/1.3NA oil-immersion objective lens and a cooled
charge-coupled device (CCD) camera. Dual emission ratio
imaging was acquired with a 420DF20 excitation filter,
a 450DRLP diachronic mirror, and two emission filters
(475DF40 for cyan and 535DF25 for yellow). The acqui-
sition was set with 200-ms exposure in both channels and
20-s elapses. Images in both channels were subjected to
background subtraction, and ratios of yellow-to-cyan color
were calculated at different time points.
Adult Myocyte-Shortening Assay
Cells were stimulated with ISO at indicated concen-
trations after treatment with or without insulin (100
nmol/L) for 30 min. Adult myocytes were placed in a
dish with HEPES buffer (34) and electrically stimulated
at 30 V/cm at 0.5 Hz at room temperature. Cell length
was recorded with a charge coupled device camera. Cell
contraction shortening was analyzed by IonOptix software
(IonOptix, Boston, MA) and normalized as the increase
over the basal levels after being fitted to a sigmoidal curve.
The maximal shortening was normalized to the baseline
value.
Western Blot Analysis
Whole-cell and heart tissue lysates were prepared in lysis
buffer (50 mmol/L Tris, pH 7.4; 2.5 mmol/L EDTA; 150
mmol/L NaCl, 25 mmol/L sodium pyrophosphate, and 1%
(v/v) NonidetP40, 1% Na-deoxycholate, 0.1% SDS, and
protease inhibitor cocktail tablets (Thermo Scientific,
Chicago, IL) after washing twice with ice-cold PBS. The
lysates without boiling were resolved by SDS-PAGE.
Proteins were transferred to a Nitrocellulose membrane
(Millipore, Billerica, MA), and incubated with the primary
antibody followed by IRDye 680CW goat-anti mouse or
with IRDye 800CW goat-anti rabbit secondary antibodies.
Specific proteins were detected by an Odyssey scanner
(LI-COR, Lincoln, NE). The primary antibodies used for
Western blotting were as follows: total and phosphor-
ylated PLB at Ser16 and Thr17 (Bradilla, Leeds, U.K.),
IR (SCBT, Santa Cruz, CA), total and phosphorylated
b2AR at Ser
261/262 (28) and Ser355/356 (SCBT), total and
phosphorylated pAkt Ser473 (Cell Signaling, Danvers,
MA), g-tubulin, GFP, and GRK2 (SCBT).
Coimmunoprecipitation
Heart tissues were used to detect endogenous protein
interactions. Heart tissues were lysed with a FastPrep-24
homogenizer for 20 s in immunoprecipitation assay buffer
(50 mmol/L Tris-HCl [pH 7.5], 150 mmol/L NaCl, 1%NP-40,
0.25% deoxycholate, 9.4 mg/50 mL sodium orthovanadate,
and 1% sodium dodecyl sulfate). Lysates were cleared by
centrifugation (40,000 rpm for 30 min at 4°C) and subjected
to immunoprecipitation with Protein A beads (Repligen,
Waltham, MA). The immunoprecipitates were resolved via
SDS-PAGE and blotted with antibodies against IR (1:500)
or b2AR (1:500). Primary antibodies were visualized with
IRDye 680CW goat anti-mouse or with IRDye 800CW goat
anti-rabbit secondary antibodies using an Odyssey scanner
(LI-COR).
Statistical Analysis
One or two-way ANOVA followed by post hoc Turkey test
or Student t test were performed using Prism (GraphPad
Software, San Diego, CA). P , 0.05 was considered sta-
tistically significant.
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RESULTS
Insulin Impairs b-Adrenergic Stimulation of
Contractility in Mouse Hearts
We hypothesized that insulin could impair adrenergic
signal transduction in the myocardium and impair
adrenergic-induced contractile responses. In Langendorff
perfused mouse hearts, insulin alone (1 nmol/L) did not
significantly affect cardiac contractility in mouse hearts as
evidenced by LV developed pressure (LVDP) (57.5 6 13.6
mmHg without insulin vs. 53.3 6 4.6 mmHg with insu-
lin), maximal +dP/dt (rate of rise of ventricular pressure)
(1,944.8 6 508.9 mmHg/s without insulin vs. 1,766.0 6
202.9 mmHg/s with insulin), and minimum –dP/dt (rate
of fall of ventricular pressure) (21,520.5 6 318.2
mmHg/s without insulin vs. 21,344.7 6 115.8 mmHg/s
with insulin). b-Adrenergic stimulation with ISO induced a
dose-dependent increase in cardiac contractility (Fig. 1A–C)
with half-maximal effective concentration (EC50) of
;0.01 nmol/L and maximal response at concentrations
.1 nmol/L. ISO increased peak LVDP from 57.5 6 13.6
to 132.7 6 5.6 mmHg (130.7%), maximal +dP/dt from
1,944.86 508.9 to 5,868.3 6 981.5 mmHg/s (201.7%), and
minimum 2dP/dt from 21,520.5 6 318.2 to 24,351.8 6
358.3 mmHg/s (186.2%). In contrast, pretreatment with
1 nmol/L of insulin significantly attenuated the ISO-
induced contractile responses, changing the EC50 by 5- to
10-fold (;0.1 nmol/L). In comparison with hearts stimu-
lated with ISO alone, the maximal responses of LVDP
(from 53.3 6 4.6 to 78.9 6 10.0 mmHg; 48.0%), +dP/dt
(from 1,766.0 6 202.9 to 2,584.5 6 156.2 mmHg/s;
46.4%), and –dP/dt (from 21,344.7 6 115.8 to 22,077.7 6
164.8 mmHg/s; 54.5%) were all substantially decreased
(Fig. 1A–C). Consistent with contractility data, adrenergic
stimulation, but not insulin stimulation, significantly in-
duced PKA phosphorylation of Ser16 and Ca2+/calmodulin-
dependent protein kinase (CaMK)II phosphorylation of
Thr17 of PLB, a critical regulator of calcium cycling that
mediates cardiac contractility. In comparison, neither
stimulation altered the expression of SERCA and the
ratio between PLB and SERCA (Supplementary Fig. 1).
However, pretreatment with insulin significantly re-
duced PKA and (CaMK)II phosphorylation of PLB in-
duced by ISO (Fig. 1D). These data suggest that insulin
blunts b-adrenergic responsiveness of cardiomyocytes,
which may contribute to impaired cardiac function in
hyperinsulinemic states.
Activation of IR by Insulin Impairs b-Adrenergic
Signaling in Cardiomyocytes in a b2AR-Dependent
Manner
We then used FRET-based biosensors AKAR3 (33)
for PKA activities to directly determine the impact of
Figure 1—Insulin inhibits bAR-induced phosphorylation of PLB and cardiac contractility in murine hearts. Mouse hearts were cannulated
for Langendorff perfusion with different concentrations of ISO in the absence or presence of pretreatment with insulin (1 nmol/L for 30 min).
The LVDP (A), maximal +dP/dt (B), and minimal 2dP/dt (C) were analyzed and plotted against doses of ISO. D: Mouse hearts were
cannulated for Langendorff perfusion with ISO (100 nmol/L for 10 min) with or without pretreatment with insulin (1 nmol/L for 30 min).
Heart lysates were used to detect phosphorylation of Akt (Ser473) and PLB at the Ser16 site (PKA site) and Thr17 site ([CaMK]II site). The
signals were normalized against their respective total proteins. n = 5. *P < 0.05; **P < 0.01, by one-way ANOVA between groups. Maxi.,
maximal; Mini., minimal.
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insulin-adrenergic signaling cross-talk on cAMP and
PKA activities in neonatal cardiomyocytes. Stimulation
of bAR with ISO induced a dose-dependent increase in
the PKA AKAR3-FRET ratio (EC50 0.43 nmol/L) (Fig. 2A
and Supplementary Fig. 2). Insulin dose-dependently
impaired ISO-induced increase(s) in the PKA AKAR3-
FRET ratio by right shifting the ISO-induced dose re-
sponse curves (EC50 3.78 nmol/L at 10 nmol/L and
EC50 38.2 nmol/L at 100 nmol/L of insulin treatment)
(Fig. 2A). Pretreatment with increasing doses of insulin
almost completely inhibited the increase(s) in PKA
AKAR3-FRET ratio induced at 1 nmol/L of ISO (Fig. 2A).
ISO (100 nmol/L) induced a robust increase in sarcomere
shortening in adult cardiomyocytes (Fig. 2B). While insulin
alone minimally affected the baseline shortening, pretreat-
ment with insulin significantly attenuated the ISO-induced
myocyte shortening (Fig. 2B). In comparison, insulin did
not affect the forskolin-induced cAMP FRET response and
myocyte contractile shortening response (Supplementary
Fig. 3). To further assess which bAR subtype signaling
was modulated by insulin, we applied the b1AR selective
agonist dobutamine or the b2AR selective agonist clenbuterol.
Dobutamine robustly increased the PKA AKAR3-FRET
ratio, which was significantly attenuated after pretreatment
with insulin (Fig. 2C). In comparison, clenbuterol in-
duced a modest increase in PKA AKAR3-FRET ratio,
which was also reduced by pretreatment with insulin
(Fig. 2C). In agreement, dobutamine, but not clenbuterol,
significantly increased myocyte contractile shortening,
which is consistent with the predominant role of b1AR
in promoting cardiac contractility in hearts (10–12). In
contrast, b2AR-induced cAMP and PKA activities are
compartmentalized along the plasma membrane and
play a minimal role in inducing phosphorylation of
PLB and the contractile response (10–12). Thus, whereas
pretreatment with insulin significantly attenuated the
dobutamine-induced contractile response (Fig. 2D), in-
sulin had little impact on contractility when cells were
exposed to clenbuterol. Consistent with the contractile
shortening data, dobutamine but not clenbuterol induced
a strong phosphorylation of Ser16 and Thr17 of PLB, which
was significantly attenuated by insulin pretreatment
(Fig. 2E–H).
We further used myocytes from mice lacking individual
bAR genes to determine which bAR subtype is involved in
insulin-induced signaling cross-talk. In wild-type neonatal
myocytes, insulin pretreatment reduced the ISO-induced
changes in cAMP ICUE3 and PKA AKAR3-FRET ratios
(Fig. 3A and B). In myocytes lacking b2ARs (b2AR-KO),
we examined the insulin effect on b1AR, the major b1AR
subtype that is responsible for cardiac contractile re-
sponse to catecholamines in the heart. Interestingly, in-
sulin did not influence ISO-induced and b1AR-mediated
increases in cAMP and PKA FRET ratio (Fig. 3A and B),
suggesting that expression and activation of b2ARs is
necessary for the insulin effect. As controls, in myocytes
lacking b1ARs (b1AR-KO), activation of b2AR induced
small increases in cAMP and PKA FRET ratios, which
were sensitive to insulin pretreatment (Fig. 3A and B).
These data indicate that despite the minor expression of
b2AR in the heart, the cross-talk between IR and b2AR is
sufficient to attenuate the cAMP signal induced by acti-
vation of both b1AR and b2AR in wild-type cells.
We then validated the cross-talk between IR and bAR
subtype signaling cascades in contractile shortening in
adult cardiomyocytes. ISO failed to increase contractile
shortening or phosphorylation of PLB in b1AR-KO myo-
cytes (Fig. 3C and D). In contrast, in b2AR-KO myocytes,
ISO induced a robust response in contractile shortening,
which was not affected by insulin pretreatment (Fig. 3E).
Consistently, ISO also promoted a strong phosphorylation
of Ser16 and Thr17 of PLB, which was not affected by
insulin pretreatment (Fig. 3F).
b2AR Is Necessary for the Inhibitory Effect of Insulin on
Cardiac Contractility in Mouse Hearts
We further validated the necessary role of b2AR in cross-
talk between IR and bAR signaling cascades in animal
hearts. In Langendorff perfused b2AR-KO mouse hearts,
b-adrenergic stimulation with ISO induced a strong in-
crease in cardiac contractility, including increased peak
LVDP, maximal +dP/dt, and minimum 2dP/dt (Fig. 4A–
C). Unlike the case of wild-type hearts, pretreatment with
1 nmol/L of insulin did not significantly attenuate the
ISO-induced contractile responses, with no reduction in
the maximal responses of LVDP, maximal +dP/dt, or min-
imal 2dP/dt (Fig. 4A–C). Consistent with contractility
data, adrenergic stimulation, but not insulin stimulation,
significantly induced PKA phosphorylation of Ser16 and
(CaMK)II phosphorylation of Thr17 of PLB (Fig. 4D).
Pretreatment with insulin did not significantly reduce
ISO-induced PKA and (CaMK)II phosphorylation of PLB
(Fig. 4D). These data confirm the essential role of b2AR
in mediating the cross-talk between IR and bARs that
impairs cardiac contractility in animal hearts.
IR and b2AR Exist in a Complex, and Insulin Induces
PKA- and GRK-Mediated Phosphorylation of b2AR in
Murine Hearts
We then sought to determine the molecular mechanism
for the IR/b2AR cross-talk in animal hearts. Isolated mouse
hearts were perfused in the Langendorff mode with or
without insulin (1 nmol/L) for 5 min. We observed signif-
icant increase(s) in phosphorylation of b2AR at Ser
261/262
(PKA sites) and Ser355/356 (GRK sites) relative to saline-
perfused controls (Fig. 5A). Meanwhile, in the hearts of
mice subjected to euglycemic-hyperinsulinemic clamps
for 60 min, we also observed significant increase(s)
in phosphorylation of b2AR at both PKA and GRK sites
in hearts obtained from hyperinsulinemic animals
(Fig. 5B). Activation of IR signaling was supported by
increased phosphorylation of Akt in hearts exposed to
insulin ex vivo and in vivo (Fig. 5A and B). In compari-
son, the protein levels of Gi were not changed by insulin
perfusion (Supplementary Fig. 4). Moreover, we found
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Figure 2—Insulin attenuates bAR-induced PKA activities and contractile responses in adult cardiomyocytes. A and C: Adult rat car-
diomyocytes expressing the PKA biosensor AKAR3 were stimulated with different concentrations of insulin and ISO as indicated (A) or
with bAR agonists (dobutamine, 1 mmol/L; or clenbuterol, 10 nmol/L) after incubation with insulin (100 nmol/L for 30 min) (C ). The
changes in the PKA FRET ratio were recorded, and the maximal increases in PKA FRET ratio were plotted. B and D: Adult rat
cardiomyocytes were stimulated with bAR agonists (dobutamine, 1 mmol/L; or clenbuterol, 10 nmol/L) after incubation with insulin
(100 nmol/L for 30 min) as indicated. Contractile shortening was recorded and plotted. n indicates the number of cells tested. E–H:
The cells were lysed to detect phosphorylation of Akt (Ser473) and PLB (Ser16 or Thr17); the phosphorylation levels were normalized
against their respective total protein. n = 4. *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA between groups as indicated. AU,
arbitrary units; Ins, insulin.
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that IRs and b2ARs form membrane complexes that may
facilitate signaling cross-talk. Coimmunoprecipitation
with anti-IR antibody showed that both receptors form
complexes in mouse hearts, but the association was signifi-
cantly reduced in hearts after exposure to insulin for 10 min
ex vivo (Fig. 5C) or in mouse hearts after euglycemic-
hyperinsulinemic clamps for 60 min in vivo (Fig. 5D).
Insulin Induces IRS-Dependent PKA and GRK
Phosphorylation of b2AR for Biased Activation of Gi in
Cardiomyocytes
Activation of IR induces downstream signaling via re-
cruitment of the adaptor signaling proteins, insulin
receptor substrates (IRSs). Deletion of either IRS1 orIRS2
in mouse hearts (35) abolished insulin-induced phosphor-
ylation of b2AR and the inhibitory effect of insulin (100
nmol/L) on the ISO-induced cAMP FRET responses (Fig.
6A and B). Inhibition of IRS autophosphorylation with
PQ401 also abolished the inhibitory effect of insulin (100
nmol/L) on the ISO-induced cAMP FRET responses (Fig.
6C). Accordingly, silencing of the IR with an IR-specific
small interfering RNA abolished the insulin effects on the
bAR-induced cAMP signal (Fig. 6D). These data suggest
that cross-talk between IR and bARs are dependent on
the interaction between the IR and IRS proteins. A recent
study indicates that insulin can promote formation of IRS-
GRK2 complexes in animal hearts (16). While different
GRKs are implicated in agonist-induced phosphorylation
Figure 3—The effects of insulin on bAR subtype signaling–induced cAMP-PKA activities and contractile responses in b1AR-KO and b2AR-
KO cardiomyocytes. Wild-type, b1AR-KO, and b2AR-KO neonatal cardiomyocytes expressing the cAMP biosensor ICUE3 (A) or PKA
biosensor AKAR3 (B) were treated with or without insulin (100 nmol/L for 30 min) prior to stimulation with ISO (100 nmol/L) or as indicated.
The changes in the cAMP FRET ratio and PKA FRET ratio were recorded, and the maximal responses were plotted. ***P< 0.001 by Student
t test relative to ISO group; n indicates the number of cells tested. Adult b1AR-KO (C) or b2AR-KO (E) myocytes paced at 0.5 Hz were
pretreated with or without insulin (100 nmol/L for 30 min) before bAR agonists (ISO, 100 nmol/L) as indicated. Contractile shortening was
recorded and plotted. ***P < 0.001 by one-way ANOVA between groups; n indicates the number of cells tested. D and F: Cells were lysed
to detect phosphorylation of Akt (Ser473) and PLB (Ser16 or Thr17); n = 4. AU, arbitrary units; WT, wild-type.
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of b2ARs in a cell type–specific manner (28,36), we have
previously shown that GRK2 is necessary for bAR agonist–
induced GRK phosphorylation of b2ARs at Ser
355/356 in
cardiomyocytes (28). Inhibition of GRK2 also abolished
the insulin-induced phosphorylation of b2ARs at GRK sites
Ser355/356 in H9C2 cardiomyoblasts (Supplementary Fig.
5A) and the insulin-mediated impairment of b-adrenergic
stimulation of cAMP signaling in neonatal cardiomyocytes
(Fig. 7A). Meanwhile, the PKA inhibitor H89 abolished the
insulin-induced phosphorylation of b2ARs at PKA sites
Ser261/262 in H9C2 cardiomyoblasts (Supplementary Fig.
5B) and partially rescued the insulin-mediated impairment
of ISO-induced cAMP FRET response in neonatal cardio-
myocytes (Fig. 7B). As a control, H89 minimally affected
the maximal cAMP signaling induced by ISO alone (Fig.
7B). We further examined the role of b2AR phosphoryla-
tion in IR-b2AR cross-talk by introducing either wild-type
or mutant b2ARs into b2AR-KO neonatal cardiomyocytes.
Insulin impaired cAMP generation induced by ISO in cells
expressing the wild-type b2AR, but the effect of insulin
was absent in the cells expressing either PKAmut b2AR
that lacks the PKA phosphorylation sites or GRKmut
b2AR that lacks the GRK phosphorylation sites (Fig.
7C). In agreement, inhibition of GRK2 by overexpressing
bARKct, a dominant negative inhibitor of GRK2, abol-
ished the inhibitory effect of insulin on the ISO-induced
PKA FRET response in neonatal myocytes and fractional
shortening in adult rat cardiomyocytes (Fig. 7D and E).
The phosphorylation of the b2AR by GRK2 and PKA
promotes receptor internalization and also switches the
receptor coupling from Gs to Gi proteins in cardiomyo-
cytes (28,37). In myocytes treated with insulin (100
nmol/L for 30 min), inhibition of Gi with pertussis toxin
(PTX) or the specific Gi inhibitor Gi-CT (38) rescued the
ISO-induced cAMP FRET response (Fig. 8A). Moreover,
inhibition of Gi with PTX abolished the inhibitory effect
of insulin on ISO-induced phosphorylation of PLB and
contractile shortening in adult cardiomyocytes (Fig. 8B).
Activation of IR has been reported to be linked to activa-
tion of phosphodiesterase 3 (PDE3) in oocytes and neu-
rons (39,40). We therefore tested whether PDE3 plays any
role in the inhibitory effect of insulin on bAR signaling in
myocytes. Inhibition of PDE3 with cilostamide partially
rescued the ISO-induced cAMP FRET response (Supple-
mentary Fig. 6). These data suggest that insulin induces
a b2AR-Gi coupling to inhibit cAMP production and myo-
cyte contractility under adrenergic stimulation in part via
activation of PDE3.
DISCUSSION
In both diabetes and heart failure, circulating insulin levels
are chronically elevated, leading to persistent stimulation
Figure 4—b2AR is necessary for the inhibitory effects of insulin on cardiac contractility. b2AR-KO mouse hearts were cannulated for
Langendorff perfusion with ISO in the absence or presence of pretreatment with insulin (1 nmol/L for 30 min). The LVDP (A), maximal +dP/dt
(B), and minimal 2dP/dt (C ) were analyzed and plotted. D: Mouse hearts were cannulated for Langendorff perfusion with ISO (100 nmol/L
for 10 min) with or without pretreatment with insulin (1 nmol/L for 30 min). Heart lysates were used to detect phosphorylation of Akt (Ser473),
PLB at Ser16 (PKA site), and Thr17 ([CaMK]II site), respectively. The signals were normalized against their respective total proteins, re-
spectively. n = 5. *P < 0.05 by one-way ANOVA between groups.
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of IRs in these clinical conditions. Despite the resistance
to Akt-mediated glucose metabolism in adipocytes and
skeletal muscle cells, the heart retains its insulin sensitivity
in terms of insulin’s ability to activate IR signaling cascades
in type 2 diabetes (2,41). The increase in insulin signaling
in myocardium promotes translocation of CD36, which
exacerbates fatty acid uptake and lipotoxicity (42). More-
over, hyperactive insulin signaling also accelerates adverse
LV remodeling in pressure overload hypertrophy (3). Here,
we show that insulin can directly impair adrenergic sig-
naling pathways for contractile function via an IR-b2AR
signaling complex in animal hearts. This study offers a po-
tential novel mechanism for cardiac dysfunction associated
with hyperinsulinemia in diabetic cardiomyopathy and
heart failure.
In animal hearts, this IR and b2AR signaling complex
channels a direct and negative impact of insulin on
b-adrenergic signaling pathways that stimulate cardiac
contractile function. These data are consistent with previ-
ous reports showing that insulin inhibits b-adrenergic
action in hearts after ischemia/reperfusion (23). Insulin
stimulation promotes cross-talk with b2AR pathways via
IRS-dependent and GRK2-mediated phosphorylation of the
adrenergic receptor, which selectively activates a Gi-biased
b2AR-signaling cascade to inhibit cAMP/PKA activities under
b-adrenergic stimulation. Consequently, this IR-b2AR cross-
talk leads to impaired b-adrenergic–induced contractile func-
tion in cardiomyocytes and perfused mouse hearts (Fig. 8C).
Previous studies show that insulin induces phosphor-
ylation of the b2AR at classic PKA phosphorylation sites
for b2AR internalization and subsequent downregulation
in human embryonic kidney (HEK)293 cells and adipo-
cytes (25–27). Here, we identified additional phosphory-
lation of the b2AR at the classic GRK sites after insulin
stimulation, which are also dependent on IRS expression
(Fig. 6) (28). Notably, the GRK-mediated phosphorylation
Figure 5—Insulin induces b2AR phosphorylation in mouse hearts. Isolated working mouse hearts were perfused with or without insulin
(1 nmol/L) prior to harvest (A). Mice were subjected to euglycemic-hyperinsulinemic clamps or to sham saline infusions for 60 min, and the
hearts were harvested (B). PKA and GRK-mediated phosphorylation of the b2AR at Ser
261/262 and Ser355/356 were detected by Western blot.
The levels of phosphorylation were normalized against total b2AR. n = 3. *P < 0.05; **P < 0.01 or ***P < 0.001 by Student t test relative to
controls. Heart lysates obtained from Langendorff perfused mouse hearts with insulin (100 nmol/L) for 10 min (C) or from animals after
sham or euglycemic-hyperinsulinemic clamps (60 min) (D) were immunoprecipitated (IP) with anti-IR antibody. The pulled-down proteins
were detected by Western blot with antibodies as indicated and normalized against their respective IP proteins. n > 3. *P < 0.05 by t test
between indicated groups. IB, immunoblot.
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of b2AR in cardiomyocytes is different from those in
HEK293 cells (36). In cardiomyocytes, GRK2 is necessary
for agonist-induced phosphorylation of Ser355/356 (28),
which we now show is promoted by activation of the
IR. The phosphorylation at GRK sites is likely due to re-
cruitment of GRK2 to the b2AR via increased association
between GRK2 and IRS proteins after insulin stimulation
(16). The signaling pathways involved in PKA phosphor-
ylation of b2AR remain to be elucidated. A prior study
reported that IR signaling intermediates downstream of
phosphatidylinositol 3-kinase may play a role in inhibiting
cAMP-mediated inotropic effects under adrenergic stimu-
lation (24), which could be linked to phosphorylation at
the PKA sites of b2AR.
After insulin stimulation, the phosphorylated b2AR
dissociates from the complex and promotes receptor/Gi
coupling. Thus, insulin signaling mimics a biased b2AR
agonist that selectively activates a Gi-biased signaling
pathway. This insulin-induced b2AR/Gi coupling is suffi-
cient to attenuate adrenergic-induced cAMP activities in
hearts. As a result, insulin blunts adrenergic-induced PKA
phosphorylation of PLB, a critical protein involved in
myocyte calcium cycling, and impairs b-adrenergic–
induced contractility in both isolated myocytes and
animal hearts. A prior study revealed that IGF-1 can
promote b1AR internalization in HEK293 cells and in-
hibit b1AR signaling in canine adult cardiomyocytes
(43). Conversely, overexpression of IGF-1 in the myocar-
dium prevents streptozotocin-induced cardiac contractile
dysfunction and restored b-adrenergic responsiveness
in isolated myocytes (44). Therefore, it remains to be
determined whether IGF-1 signaling modulates b1AR sig-
naling in cardiomyocytes via mechanisms that are dis-
tinct from those of insulin.
Accumulating evidence also indicates that adrenergic
signaling may modulate insulin signal transduction path-
ways that regulate glucose uptake in adipocytes and
skeletal and cardiac muscle cells (8,16,18,20). Reduced
b2AR expression in aged animals contributes to glucose
intolerance, and overexpression of the b2AR can rescue
this phenotype (45). Evidence also suggests that Akt could
be a key mechanism underlying the impact of b-adrenergic
stimulation on insulin-induced glucose uptake (46,47),
although precise molecular signaling mechanisms remain
to be elucidated. This newly identified IR-b2AR complex
herein reported may provide a molecular basis to under-
stand and reconcile recent studies showing that bAR ac-
tivation impairs insulin-induced Akt activation, GLUT4
Figure 6—IR and IRS proteins are necessary for insulin-induced phosphorylation of b2AR and inhibition of adrenergic signaling. A: Cardiac-
restricted IRS1-KO and IRS2-KO mice were injected with ISO, and the changes in phosphorylation of b2AR at the PKA site Ser
262 and GRK
site Ser355/356 were detected with antibodies, respectively, and normalized against the total b2AR. *P< 0.05, by one-way ANOVA relative to
wild-type (WT) controls; n = 4. IRS1-KO and IRS2-KO (B) and wild-type (C and D) neonatal cardiomyocytes that expressed the cAMP
biosensor ICUE3 together with scrambled, IR-specific shRNA were treated with PQ401 (5 mmol/L for 2 h) and insulin (100 nmol/L for 30 min)
before stimulation with ISO (100 nmol/L) as indicated. The changes in the cAMP FRET ratio were recorded, and the maximal increases in
cAMP FRET ratio were plotted. **P < 0.01, ***P< 0.001 by Student t test relative to ISO group; n indicates the number of cells tested. ERK,
extracellular signal–related kinase; Scr., scramble; shRNA, small hairpin RNA.
diabetes.diabetesjournals.org Fu and Associates 2685
translocation, and glucose uptake in cardiomyocytes,
adipocytes, and skeletal muscle cells (16,19,48,49).
The novel observations made in this report are of
translational significance. Diabetes and insulin resistance
are associated with altered cardiac structure and function
independently of coronary artery disease and ischemia
(50). Moreover, impaired inotropic reserve to dobutamine
was observed in humans with type 2 diabetes in the ab-
sence of coronary artery disease (51). Given that type 2
diabetes in humans is associated with hyperinsulinemia
and activation of myocardial insulin signaling (2), our
findings provide a plausible mechanism for impaired myo-
cardial inotropic reserve in individuals with type 2 diabe-
tes. Diabetes also increases the risk of heart failure (52),
and heart failure is an insulin-resistant state (2). If the
present findings that hyperinsulinemia may inhibit b1AR
signaling via Gi-biased b2AR signaling hold true in humans,
then the possibility is raised that hyperinsulinemic subjects
with type 2 diabetes and heart failure might have increased
sensitivity to cardio-depressive effects of nonselective or
b1 blockade, which currently represent the standard of
care for managing patients with heart failure. Furthermore,
Figure 7—Insulin induces GRK2-dependent inhibition of bAR-induced cAMP activities and contractile shortening in cardiomyocytes. A and
B: The ISO (100 nmol/L)-induced changes in the cAMP FRET ratio were recorded in neonatal cardiomyocytes with GRK2 shRNA or PKA
inhibitor H89 after incubation with insulin (100 nmol/L for 30 min) as indicated. The maximal increases in cAMP FRET ratio were plotted. C:
b2AR-KO neonatal cardiomyocytes expressing wild-type or mutant b2ARs harboring either the PKA (PKAmut) or GRK (GRKmut) phosphor-
ylation sites. The ISO (100 nmol/L)-induced changes in the cAMP FRET ratio were recorded after treatment with insulin (100 nmol/L) for
30 min. The maximal increases in cAMP FRET ratio were plotted. D and E: The ISO (100 nmol/L)-induced changes in the PKA FRET ratio
and contractile shortening were recorded in adult rat cardiomyocytes expressing the GRK2 inhibitor bARKct after incubation with insulin
(100 nmol/L for 30 min) as indicated. The maximal increases in PKA FRET ratio were plotted. *P < 0.05, **P < 0.01, and ***P < 0.001 by
one-way ANOVA or Student t test relative to the ISO group or between group pairs as indicated; n indicates the number of cells tested. Scr.,
scramble; shRNA, small hairpin RNA.
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the current study raises the interesting question of
whether specific modulation of b2-adrenergic receptor
signaling could influence the pathophysiology of diabetic
cardiomyopathy or play a role in managing heart failure
in diabetic or obese patients with hyperinsulinemia.
More broadly, the IR-bAR signaling cross-talk herein de-
scribed offers a new platform with which to explore the
broad implications of myocardial insulin signaling in
Figure 8—Insulin induces Gi-dependent inhibition of bAR-induced cAMP activities and contractile shortening in cardiomyocytes. A:
Neonatal cardiomyocytes expressing the cAMP biosensor ICUE3 together with Gi-ct, a Gi-specific inhibitor, were stimulated with ISO
(100 nmol/L) after incubation with PTX (1 mg/mL for 3 h) and insulin (100 nmol/L for 30 min) as indicated. The maximal increases in cAMP
FRET ratio were plotted. B: Adult rat cardiomyocytes were treated with ISO (100 nmol/L) after incubation with PTX (1 mg/mL for 3 h) and
insulin (100 nmol/L for 30 min) as indicated, and the fractional shortening was recorded. *P< 0.05, **P< 0.01, and ***P< 0.001 by one-way
ANOVA between groups; n indicates the number of cells tested. C: Working model of the IR-b2AR signaling network in cardiomyocytes for
contractile responses. AC, adenylate cyclase; Gi, inhibitory G protein; Gs, stimulatory G protein.
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heart failure, which is an insulin-resistant and hyperin-
sulinemic state.
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